Expression of PD-1 and CTLA-4 Ligands in Invasive Bladder Cancer Mouse Models

被引：0
|
作者：
Allam, M. [1 ]
Ismail, N. F. [1 ]
Lightbody, R. [1 ]
Fraser, S. [2 ]
Sansom, O. J. [3 ]
Iwata, T. [1 ]
机构：
[1] Univ Glasgow, Sch Med, Glasgow, Lanark, Scotland
[2] Queen Elizabeth Univ Hosp, Dept Pathol, Glasgow, Lanark, Scotland
[3] Beatson Inst Canc Res, Glasgow, Lanark, Scotland
来源：
JOURNAL OF PATHOLOGY | 2016年 / 240卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [21] CTLA-4 and PD-1 pathway blockade: combinations in the clinic
    Callahan, Margaret K.
    Postow, Michael A.
    Wolchok, Jedd D.
    FRONTIERS IN ONCOLOGY, 2015, 4
  • [22] PD-1 and CTLA-4: Two checkpoints, one pathway?
    Walker, Lucy S. K.
    SCIENCE IMMUNOLOGY, 2017, 2 (11)
  • [23] Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma
    Kahlmeyer, Andreas
    Stoehr, Christine G.
    Hartmann, Arndt
    Goebell, Peter J.
    Wullich, Bernd
    Wach, Sven
    Taubert, Helge
    Erlmeier, Franziska
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (05)
  • [24] EXPRESSION OF PD-1 AND CTLA-4 IS INCREASED DURING SYMPTOMATIC PHASE OF ACUTE HEPATITIS A
    Kim, C. W.
    Cho, H.
    Kim, H. Y.
    Lee, S. W.
    Jang, J. W.
    Choi, J. Y.
    Yoon, S. K.
    Lee, C. D.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S140 - S141
  • [25] Effects and Mechanisms of Checkpoint Inhibitors (CTLA-4, PD-1 and PD-L1 Inhibitors) as New Immunotherapeutic Agents for Bladder Cancer
    Celik, Serdar
    Altun, Zekiye Sultan
    Aktas, Safiye
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2018, 17 (01): : 18 - 25
  • [26] PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
    Porcellato, Ilaria
    Mecocci, Samanta
    Brachelente, Chiara
    Cappelli, Katia
    Armando, Federico
    Tognoloni, Alessia
    Chiaradia, Elisabetta
    Stefanetti, Valentina
    Mechelli, Luca
    Pepe, Marco
    Gialletti, Rodolfo
    Passeri, Benedetta
    Ghelardi, Alessandro
    Razzuoli, Elisabetta
    ANIMALS, 2021, 11 (07):
  • [27] Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
    Lewis, Katherine E.
    Selby, Mark J.
    Masters, Gregg
    Valle, Jose
    Dito, Gennaro
    Curtis, Wendy R.
    Garcia, Richard
    Mink, Kathy A.
    Waggie, Kimberly S.
    Holdren, Matthew S.
    Grosso, Joseph F.
    Korman, Alan J.
    Jure-Kunkel, Maria
    Dillon, Stacey R.
    ONCOIMMUNOLOGY, 2018, 7 (01):
  • [28] GENERALIZABILITY OF POTENTIAL BIOMARKERS OF RESPONSE TO CTLA-4 AND PD-1 BLOCKADE THERAPY IN CANCER
    Bortone, Dante
    Vensko, Steven
    Entwistle, Sarah
    Cogdill, Alexandria
    Monette, Anne
    Najjar, Yana
    Sweis, Randy
    Tschernia, Nicholas
    Wennerberg, Erik
    Bommareddy, Praveen
    Haymaker, Cara
    Khan, Uqba
    McGee, Heather
    Park, Wungki
    Sater, Houssein
    Spencer, Christine
    Ascierto, Maria
    Barsan, Valentin
    Popat, Vinita
    Valpione, Sara
    Wells, Danny
    Thorsson, Vesteinn
    Zappasodi, Roberta
    Rudqvist, Nils
    Vincent, Benjamin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A46 - A47
  • [29] Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
    De Silva, Pushpamali
    Aiello, Marco
    Gu-Trantien, Chunyan
    Migliori, Edoardo
    Willard-Gallo, Karen
    Solinas, Cinzia
    INTERNATIONAL JOURNAL OF CANCER, 2021, 149 (01) : 31 - 41
  • [30] Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
    Cheng, Weishi
    Kang, Kai
    Zhao, Ailin
    Wu, Yijun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
12345